SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

$ELAN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ELAN alert in real time by email
SC 13G/A 1 elana6_21224.htm PRIMECAP MANAGEMENT CO/CA/ elana6_21224.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 6)*
Elanco Animal Health Inc
(Name of Issuer)
COM
(Title of Class of Securities)
28414H103
(CUSIP Number)
December 31, 2023
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[X] Rule 13d-1(b)
[   ] Rule 13d-1(c)
[   ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
CUSIP No.: 28414H103
       
1
NAME OF REPORTING PERSON
PRIMECAP Management Company
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
95-3868081
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [   ]
(b) [   ]
3 SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
SOLE VOTING POWER
47,570,754
6
SHARED VOTING POWER
0
7
SOLE DISPOSITIVE POWER
50,600,324
8
SHARED DISPOSITIVE POWER
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
50,600,324
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[   ]
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.27%
12
TYPE OF REPORTING PERSON
IA
CUSIP No.: 28414H103
ITEM 1(a). NAME OF ISSUER:
Elanco Animal Health Inc
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
2500 Innovation Way, Greenfield, IN 46140
ITEM 2(a). NAME OF PERSON FILING:
PRIMECAP Management Company
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
ITEM 2(c). CITIZENSHIP:
U.S.A.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
COM
ITEM 2(e). CUSIP NUMBER:
28414H103
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
(a)
[ ]
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
(b)
[ ]
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
[ ]
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
[ ]
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e)
[X]
An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
(f)
[ ]
An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
(g)
[ ]
A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
(h)
[ ]
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
[ ]
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
[ ]
A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
(k)
[ ]
Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
ITEM 4. OWNERSHIP
(a) Amount beneficially owned:
50,600,324
(b) Percent of class:
10.27%
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote:
47,570,754
(ii) shared power to vote or to direct the vote:
0
(iii) sole power to dispose or direct the disposition of:
50,600,324
(iv) shared power to dispose or to direct the disposition of:
0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not Applicable
ITEM 10. CERTIFICATION:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No.: 28414H103
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 12 2024
PRIMECAP Management Company
By:
/s/ Julietta Martikyan
Name:
Julietta Martikyan
Title:
Director of Compliance and Administration
Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
Get the next $ELAN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELAN

DatePrice TargetRatingAnalyst
12/9/2024$18.00Buy
UBS
12/2/2024$14.00Market Perform
Leerink Partners
9/19/2024$17.00 → $15.00Overweight → Equal-Weight
Morgan Stanley
1/5/2024$13.00 → $20.00Hold → Buy
Stifel
12/19/2023$17.00Buy
Jefferies
12/15/2023$16.00Equal-Weight → Overweight
Morgan Stanley
12/7/2023$18.00Outperform
Exane BNP Paribas
4/20/2023$14.00Equal Weight → Overweight
Barclays
More analyst ratings

$ELAN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

    GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P. (JP) Bilbrey, Kathy Turner and Craig Wallace have each informed the Board they will not stand for re-election at the conclusion of their terms at the 2025 Annual Meeting of Shareholders.William F. (Bill) Doyle has resigned from the Board, effective immediately, in connection with entering into a research agreement with Elanco through hi

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

    GREENFIELD, Ind., Feb. 25, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the company's innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle. Medgene reports the vaccine has met all requirements of the U.S. Department of Agriculture's (USDA) platform technology guidelines and is in the final stages of review for conditional license approval. While the poultry in

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco to Participate in Upcoming Investor Conferences

    GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that the Company will participate in the following investor conferences. On Thursday, February 27, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2025 Animal Health Summit at 12:30 p.m. ET. On Monday, March 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference at 3:10 p.m. ET. On Tuesday, March 11, Todd Young, executive vice president and CFO,

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELAN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ELAN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELAN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELAN
SEC Filings

See more

$ELAN
Leadership Updates

Live Leadership Updates

See more
  • Elanco Strengthens Board of Directors with Addition of Stacey Ma

    Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

    New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

    GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELAN
Financials

Live finance-specific insights

See more
  • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

    GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Acquires Speke Contract Manufacturing Facility, Securing Key Supply Chain

    GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement

    GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELAN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more